Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,331.7% | – | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 1,369% | – | – | – |
| EPS Diluted | 2.19 | -4.48 | -9.93 | -10.09 |
| % Growth | 148.9% | 54.9% | 1.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |